Intracranial Biodegradable Silica-Based Nimodipine Drug Release Implant for Treating Vasospasm in Subarachnoid Hemorrhage in an Experimental Healthy Pig and Dog Model

Abstract EN

Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage.

When administrated orally or intravenously, systemic hypotension is an undesirable side effect.

Intracranial subarachnoid delivery of nimodipine during aneurysm clipping may be more efficient way of preventing vasospasm and DCI due to higher concentration of nimodipine in cerebrospinal fluid (CSF).

The risk of systemic hypotension may also be decreased with intracranial delivery.

We used animal models to evaluate the feasibility of surgically implanting a silica-based nimodipine releasing implant into the subarachnoid space through a frontotemporal craniotomy.

Concentrations of released nimodipine were measured from plasma samples and CSF samples.

Implant degradation was followed using CT imaging.

After completing the recovery period, full histological examination was performed on the brain and meninges.

The in vitro characteristics of the implant were determined.

Our results show that the biodegradable silica-based implant can be used for an intracranial drug delivery system and no major histopathological foreign body reactions were observed.

CT imaging is a feasible method for determining the degradation of silica implants in vivo.

The sustained release profiles of nimodipine in CSF were achieved.

Compared to a traditional treatment, higher nimodipine CSF/plasma ratios can be obtained with the implant.